Myriad Genetics, Inc.
US ˙ NasdaqGS ˙ US62855J1043

SecurityMYGN / Myriad Genetics, Inc.
InstitutionAmundi
Latest Disclosed Ownership27,976 shares
Latest Disclosed Value $ 125,892
Amundi reports 79.23% increase in ownership of MYGN / Myriad Genetics, Inc.

On May 15, 2026 - Amundi filed a 13F-HR form disclosing ownership of 27,976 shares of Myriad Genetics, Inc. (US:MYGN) valued at $125,892 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 15,609 shares of Myriad Genetics, Inc.. This represents a change in shares of 79.23% during the quarter. The current value of the position is $123,094 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F MYRIAD GENETICS COM 62855J104 27,976 12,367 79.23 126 31.58 0.0000
2026-02-17 2025-12-31 13F MYRIAD GENETICS COM 62855J104 15,609 842 5.70 96 -18.80 0.0000
2025-11-14 2025-09-30 13F MYRIAD GENETICS COM 62855J104 14,767 -98,428 -86.95 118 -81.63 0.0000
2025-08-13 2025-06-30 13F MYRIAD GENETICS COM 62855J104 113,195 76,330 207.05 637 105.48 0.0002
2025-05-15 2025-03-31 13F MYRIAD GENETICS COM 62855J104 36,865 -7,113 -16.17 310 -52.23 0.0001
2025-02-07 2024-12-31 13F MYRIAD GENETICS COM 62855J104 43,978 27,989 175.05 650 56.39 0.0002
2024-11-13 2024-09-30 13F MYRIAD GENETICS COM 62855J104 15,989 1,892 13.42 415 18.23 0.0002
2024-08-14 2024-06-30 13F MYRIAD GENETICS COM 62855J104 14,097 -6,265 -30.77 352 -6.65 0.0001
2024-05-15 2024-03-31 13F MYRIAD GENETICS COM 62855J104 20,362 3,934 23.95 377 26.60 0.0002
2024-02-14 2023-12-31 13F MYRIAD GENETICS COM 62855J104 16,428 5,985 57.31 297 96.69 0.0001
2023-11-14 2023-09-30 13F MYRIAD GENETICS COM 62855J104 10,443 -15 -0.14 152 -37.60 0.0001
2023-08-14 2023-06-30 13F MYRIAD GENETICS COM 62855J104 10,458 -940 -8.25 243 -8.68 0.0001
2023-05-15 2023-03-31 13F MYRIAD GENETICS COM 62855J104 11,398 11,398 265 0.0001
2021-11-15 2021-09-30 13F MYRIAD GENETICS COM 62855J104 0 -136,000 -100.00 0 -100.00
2021-08-16 2021-06-30 13F MYRIAD GENETICS COM 62855J104 136,000 136,000 4 0.0029
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.